Literature DB >> 21965762

Clinicopathological study of poorly differentiated colorectal adenocarcinomas: comparison between solid-type and non-solid-type adenocarcinomas.

Koji Komori1, Yukihide Kanemitsu, Seiji Ishiguro, Yasuhiro Shimizu, Tsuyoshi Sano, Seiji Ito, Tetsuya Abe, Yoshiki Senda, Kazunari Misawa, Yuichi Ito, Norihisa Uemura, Tomoyuki Kato.   

Abstract

AIM: We aimed to clarify the clinicopathological features of poorly differentiated colorectal adenocarcinomas and to define two subtypes of these adenocarcinomas. PATIENTS AND METHODS: We enrolled 78 patients, who had undergone surgery for poorly differentiated colorectal adenocarcinoma. On the basis of the microscopy results, the Por1 type is characterized by cancer cells with solid growth and little stroma; most cells contained round-shaped nuclei. The Por2 type is characterized by cancer cells with a predominantly trabecular structure; these tumors are rich in fibrous stroma. The two groups were compared for clinicopathological factors.
RESULTS: The frequency of metastasis of the lymph node, liver, lung, and peritoneum in the Por2 group was significantly higher than that in the Por1 group. The survival rate in the Por2 group was lower than that in the Por1 group.
CONCLUSION: The classification system described in this study is a simple and easy method for predicting poorly differentiated colorectal adenocarcinomas, and the prognosis of patients with Por2 tended to be unfavorable than that of Por1.

Entities:  

Mesh:

Year:  2011        PMID: 21965762

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Necessary circumferential resection margins to prevent rectal cancer relapse after abdomino-peranal (intersphincteric) resection.

Authors:  Koji Komori; Kenya Kimura; Takashi Kinoshita; Seiji Ito; Tetsuya Abe; Yoshiki Senda; Kazunari Misawa; Yuichi Ito; Norihisa Uemura; Seiji Natsume; Ryosuke Kawai; Yasuhiro Shimizu
Journal:  Langenbecks Arch Surg       Date:  2016-02-17       Impact factor: 3.445

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.